Last updated: February 20, 2026
What is NDC 00093-3160?
NDC 00093-3160 corresponds to Afluria, an influenza vaccine manufactured by Seqirus. It is an injectable vaccine approved for prevention of influenza in adults and children, typically administered during flu season.
Market Size and Demand Drivers
Annual Influenza Vaccine Market
- Global influenza vaccine market valued at approximately $4.5 billion in 2022.
- Compound annual growth rate (CAGR) projected at 7.5% from 2023 to 2028.
US Market Dynamics
- The US accounts for around 50% of global influenza vaccine sales.
- In 2022, approximately 169 million doses administered domestically.
- Peak demand occurs during the fall and winter seasons, with EUA and CDC recommendations influencing uptake.
Key Competitors
| Product |
Manufacturer |
Approximate Market Share (2022) |
Notes |
| Fluzone |
Sanofi |
35% |
Largest share in US |
| FluLaval |
GSK |
20% |
Also prominent in Europe |
| Flucelvax |
Seqirus |
15% |
Cell-based technology |
| Afluria |
Seqirus |
10% |
Focused on specific demographics |
| Others |
Various |
20% |
Includes Fluarix, Fluzone High-Dose, etc. |
Distribution Channels
- Retail pharmacies (CVS, Walgreens)
- Hospitals and clinics
- Public health programs and government procurement
Regulatory Status
- Approved by the FDA for use in ages 6 months and older.
- Fully licensed for seasonal influenza vaccination.
- No recent pending regulatory actions; supplemental approvals involve strain updates.
Price Analysis
Current Pricing Trends
| Channel |
Price per Dose (USD) |
Notes |
| Wholesale (bulk) |
$10 - $20 |
Discounts apply for large orders |
| Retail pharmacy |
$25 - $35 |
Includes markup and pharmacy fees |
| Public health programs |
Free or low-cost |
Subsidized via government contracts |
Pricing Variability Factors
- Vaccine formulation: Trivalent vs Quadrivalent.
- Packaging: Single-dose vials, multidose vials, prefilled syringes.
- Market segment: Private pay vs government-sponsored programs.
- Purchase volume: Larger contracts command lower per-dose costs.
Future Price Outlook (2023-2028)
- Expected stabilization around $15-$25 per dose in the retail channel.
- Volume-based discounts to be maintained or increased, especially in public sector procurement.
Impact of New Competitors and Technology
- Cell-based and recombinant vaccines (e.g., Flucelvax, Flublok) assume a growing market share.
- Pricing pressures may increase due to increased competition and manufacturing efficiencies.
Market and Price Projections
| Year |
Estimated Market Size (Doses) |
Projected Price per Dose |
Estimated Revenue (USD billions) |
| 2023 |
180 million |
$20 |
3.6 |
| 2024 |
185 million |
$20 |
3.7 |
| 2025 |
190 million |
$21 |
3.99 |
| 2026 |
195 million |
$21 |
4.10 |
| 2027 |
200 million |
$22 |
4.4 |
Assumptions: Steady uptake aligned with seasonal sales; no major regulatory or supply disruptions; competitive pressures moderate price increases.
Strategic Considerations
- Market Penetration: Afluria's focus on pediatric and adult markets requires targeted marketing and supply chain optimization.
- Pricing Strategies: Negotiating bulk deals with public health agencies remains critical for volume growth.
- Innovation Impact: Development of longer-lasting vaccines or universal flu vaccines could affect future demand and pricing.
Key Takeaways
- The influenza vaccine market is growing at a CAGR of 7.5%, driven by increasing global demand.
- NDC 00093-3160 (Afluria) holds approximately 10-15% market share among influenza vaccines.
- Current pricing ranges from $10 to $35 per dose, depending on channel and formulation.
- Price projections suggest stability with gradual increases, reaching around $22 by 2027.
- Competition from cell-based and recombinant vaccines will influence pricing and market share dynamics.
FAQs
1. What factors influence the price of Afluria?
Pricing is affected by formulation type (trivalent vs quadrivalent), packaging method, purchase volume, and distribution channel.
2. How does Afluria compare to other influenza vaccines?
Afluria's market share is smaller than Fluzone but competitive with Flucelvax. Price points are similar, with slight variations based on formulation and packaging.
3. What are the key growth opportunities for Afluria?
Expanding distribution in emerging markets and government procurement channels can fuel growth. Developing high-dose or adjuvanted versions may also increase demand.
4. How could new vaccine technologies impact the market?
Universal flu vaccines or longer-lasting formulations could reduce the frequency of vaccination, impacting influenza vaccine sales volume.
5. What are the regulatory risks for Afluria?
Regulatory changes affecting strain updates or approval requirements for different age groups could influence sales and market share.
Sources:
[1] Global Influenza Vaccines Market Report, 2023.
[2] U.S. CDC Influenza Vaccine Supply and Distribution Data, 2022.
[3] Pharma Market Outlook 2023-2028.
